Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.39 |
| ▸ | HTT | P42858 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269493 | 0.93 | HTT (0.38) | KMT2AMEN1MAPTGAALMNA | |
| SCHEMBL1269665 | 0.92 | HTT (0.40) | KMT2AMEN1MAPTLMNASMN1; SMN2 | |
| SCHEMBL1269770 | 0.90 | GAA (0.42) | KMT2AMEN1MAPTGAALMNA | |
| SCHEMBL1269539 | 0.89 | KMT2A (0.43) | KMT2AMEN1MAPTGAALMNA | |
| SCHEMBL1269717 | 0.89 | MEN1 (0.44) | KMT2AMEN1MAPTGAALMNA | |
| SCHEMBL1269360 | 0.86 | KMT2A (0.44) | KMT2AMEN1MAPTGAALMNA | |
| SCHEMBL1269706 | 0.86 | ALDH1A1 (0.42) | KMT2AMEN1MAPTGAALMNA | |
| SCHEMBL1269715 | 0.84 | MEN1 (0.43) | KMT2AMEN1MAPTGAALMNA | |
| SCHEMBL1268967 | 0.84 | PTGDR (0.36) | — | |
| SCHEMBL1269948 | 0.84 | PTGDR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1786782-B1 | BISARYL-SULFONAMIDES | AMGEN INC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060084802-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221584-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | KMT2A 1448/4885MEN1 4841/4885MAPT 4602/4885 |
| US-20060084802-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | KMT2A 1448/4885MEN1 4841/4885MAPT 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.